194 related articles for article (PubMed ID: 21557735)
1. VS-105: a novel vitamin D receptor modulator with cardiovascular protective effects.
Wu-Wong JR; Kawai M; Chen YW; Nakane M
Br J Pharmacol; 2011 Sep; 164(2b):551-60. PubMed ID: 21557735
[TBL] [Abstract][Full Text] [Related]
2. Two novel vitamin D receptor modulators with similar structures exhibit different hypercalcemic effects in 5/6 nephrectomized uremic rats.
Wu-Wong JR; Kawai M; Chen YW; Wessale JL; Huang CJ; Wu MT; Nakane M
Am J Nephrol; 2013; 37(4):310-9. PubMed ID: 23548814
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.
Wu-Wong JR; Chen YW; Wessale JL
Am J Physiol Renal Physiol; 2015 Feb; 308(4):F309-19. PubMed ID: 25503724
[TBL] [Abstract][Full Text] [Related]
4. Cardiac effect of vitamin D receptor modulators in uremic rats.
Mizobuchi M; Ogata H; Yamazaki-Nakazawa A; Hosaka N; Kondo F; Koiwa F; Kinugasa E; Shibata T
J Steroid Biochem Mol Biol; 2016 Oct; 163():20-7. PubMed ID: 27072785
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats.
Sawada K; Wu-Wong JR; Chen YW; Wessale JL; Kanai G; Kakuta T; Fukagawa M
J Steroid Biochem Mol Biol; 2017 Mar; 167():48-54. PubMed ID: 27989797
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease.
Fujii H; Yonekura Y; Nakai K; Kono K; Goto S; Nishi S
J Steroid Biochem Mol Biol; 2017 Mar; 167():55-60. PubMed ID: 27818277
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of VS-105: A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects.
Chen B; Kawai M; Wu-Wong JR
Bioorg Med Chem Lett; 2013 Nov; 23(21):5949-52. PubMed ID: 24035340
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
Noonan W; Koch K; Nakane M; Ma J; Dixon D; Bolin A; Reinhart G
Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.
Mizobuchi M; Finch JL; Martin DR; Slatopolsky E
Kidney Int; 2007 Sep; 72(6):709-15. PubMed ID: 17597697
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet.
Lau WL; Leaf EM; Hu MC; Takeno MM; Kuro-o M; Moe OW; Giachelli CM
Kidney Int; 2012 Dec; 82(12):1261-70. PubMed ID: 22932118
[TBL] [Abstract][Full Text] [Related]
11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies.
Czaya B; Seeherunvong W; Singh S; Yanucil C; Ruiz P; Quiroz Y; Grabner A; Katsoufis C; Swaminathan S; Abitbol C; Rodriguez-Iturbe B; Faul C; Freundlich M
Am J Hypertens; 2019 Jan; 32(1):34-44. PubMed ID: 30329020
[TBL] [Abstract][Full Text] [Related]
13. Different vitamin D receptor agonists exhibit differential effects on endothelial function and aortic gene expression in 5/6 nephrectomized rats.
Wu-Wong JR; Li X; Chen YW
J Steroid Biochem Mol Biol; 2015 Apr; 148():202-9. PubMed ID: 25500070
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of vitamin D analogs on vascular calcification.
Cardús A; Panizo S; Parisi E; Fernandez E; Valdivielso JM
J Bone Miner Res; 2007 Jun; 22(6):860-6. PubMed ID: 17352647
[TBL] [Abstract][Full Text] [Related]
15. FGF23 and the PTH response to paricalcitol in chronic kidney disease.
D'Arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
Eur J Clin Invest; 2020 Feb; 50(2):e13196. PubMed ID: 31863599
[TBL] [Abstract][Full Text] [Related]
16. How dietary phosphate, renal failure and calcitriol administration affect the serum calcium-phosphate relationship in the rat.
Jara A; Chacón C; Felsenfeld AJ
Nephrol Dial Transplant; 2002 May; 17(5):765-71. PubMed ID: 11981061
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular disease in chronic kidney failure: the role of VDR activators.
Wu-Wong JR; Tian J; Nakane M; Ma J; Fey TA; Kroeger P; Fryer RM; Reinhart GA
Curr Opin Investig Drugs; 2006 Mar; 7(3):206-13. PubMed ID: 16555680
[TBL] [Abstract][Full Text] [Related]
18. A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action.
Hirata M; Endo K; Katsumata K; Ichikawa F; Kubodera N; Fukagawa M
Nephrol Dial Transplant; 2002; 17 Suppl 10():41-5. PubMed ID: 12386268
[TBL] [Abstract][Full Text] [Related]
19. The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival?
Covic A; Voroneanu L; Goldsmith D
Nephron Clin Pract; 2010; 116(3):c187-95. PubMed ID: 20606478
[TBL] [Abstract][Full Text] [Related]
20. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.
Slatopolsky E; Finch J; Ritter C; Takahashi F
Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S40-7. PubMed ID: 9808142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
